LeMaitre Vascular Prices $150 Million Convertible Senior Notes

Offering Details - LeMaitre Vascular announced the pricing of its offering of $150,000,000 aggregate principal amount of 2.50$22,500,000 in notes [1] - The notes will accrue interest at 2.50% per annum, payable semi-annually starting August 1, 2025, and will mature on February 1, 2030 [2] - The initial conversion rate is 8.3521 shares of common stock per $1,000 principal amount of notes, representing a 30$92.10 per share [2] Conversion and Redemption Terms - Noteholders can convert their notes under certain conditions before August 1, 2029, and at any time thereafter until the second scheduled trading day before maturity [2] - The company may redeem the notes in whole or in part starting February 5, 2028, if the stock price exceeds 130% of the conversion price for a specified period [3] - If a "fundamental change" occurs, noteholders may require the company to repurchase their notes at the principal amount plus accrued interest [4] Use of Proceeds - The company estimates net proceeds of approximately $145.9 million ($167.8 million if the option to purchase additional notes is fully exercised) after deducting discounts, commissions, and offering expenses [5] - The proceeds will be used for working capital, general corporate purposes, and potential acquisitions or investments in complementary companies, product lines, products, or technologies [6] Company Overview - LeMaitre Vascular is a provider of devices, implants, and services for the treatment of peripheral vascular disease, which affects over 200 million people worldwide [9] - The company develops, manufactures, and markets disposable and implantable vascular devices targeting vascular surgeons [9]